Mutual antagonism of target of rapamycin and calcineurin signaling by Mulet, J. M. et al.
Mutual Antagonism of Target of Rapamycin and
Calcineurin Signaling*
Received for publication,May 3, 2006, and in revised form, September 6, 2006 Published, JBC Papers in Press, September 7, 2006, DOI 10.1074/jbc.M604244200
Jose M. Mulet1, Dietmar E. Martin, Robbie Loewith2, and Michael N. Hall3
From the Biozentrum, University of Basel, Klingelbergstrasse 70, CH 4056 Basel, Switzerland
Growth and stress are generally incompatible states. Stressed
cells adapt to an insult by restraining growth, and conversely,
growing cells keep stress responses at bay. This is evident in
many physiological settings, including for example, the effect of
stress on the immune or nervous system, but the underlying
signaling mechanisms mediating such mutual antagonism are
poorly understood. In eukaryotes, a central activator of cell
growth is the protein kinase target of rapamycin (TOR) and its
namesake signaling network. Calcineurin is a conserved, Ca2/
calmodulin-dependent protein phosphatase and target of the
immunosuppressant FK506 (tacrolimus) that is activated in
yeast during stress to promote cell survival. Here we show yeast
mutants defective for TOR complex 2 (TORC2) or the essential
homologous TORC2 effectors, SLM1 and SLM2, exhibited con-
stitutive activation of calcineurin-dependent transcription and
actin depolarization. Conversely, cells defective in calcineurin
exhibited SLM1 hyperphosphorylation and enhanced interac-
tion between TORC2 and SLM1. Furthermore, a mutant SLM1
protein (SLM1C14) lacking a sequence related to the consensus
calcineurin docking site (PxIxIT) was insensitive to calcineurin,
and SLM1C14 slm2 mutant cells were hypersensitive to oxida-
tive stress. Thus, TORC2-SLM signaling negatively regulates
calcineurin, and calcineurin negatively regulates TORC2-SLM.
These findings provide a molecular basis for the mutual antag-
onism of growth and stress.
TOR5 is a serine/threonine kinase and a central controller of
cell growth. TOR is found in two structurally and functionally
distinct, evolutionarily conserved protein complexes, TORC1
and TORC2 (1–3). TORC1 is rapamycin-sensitive and controls
several growth-related processes including transcription,
translation, ribosome biogenesis, nutrient transport, and auto-
phagy in response to nutrient, energy, and (in metazoans)
growth factor signals (3). TORC2 is rapamycin-insensitive and
controls polarization of the actin cytoskeleton via a ROM2-
RHO-PKC1-MPK1/SLT2 effector pathway (4, 5). Thus, TOR
via its two complexes integrates temporal and spatial control of
cell growth.
In the yeast Saccharomyces cerevisiae, calcineurin promotes
cell survival upon environmental stress (6). In response to a
stress-induced increase in cytoplasmic calcium, calcineurin
dephosphorylates and activates several cytoplasmic targets.
The calcineurin docking site in target proteins consists of the
consensus sequence PxIxIT. The best characterized calcineurin
target in yeast is the transcription factor CRZ1/TCN1/HAL8
(7–9). Dephosphorylated CRZ1 translocates into the nucleus
and activates target genes containing a calcineurin-dependent
response element. These genes are involved mainly in ion
homeostasis, vesicular transport, and cell wall maintenance.
Independent of transcription, calcineurin also mediates stress-
induced depolarization of the actin cytoskeleton and a delay in
the G2–M transition of the cell cycle (10, 11). Calcineurin is a
heterodimer composed of a positive regulatory subunit (CNB1)
and in S. cerevisiae, one of the redundant catalytic subunits
CNA1 and CNA2.
Cells respond to environmental stress by down-regulating
energy demanding growth processes and up-regulating survival
processes. How do cells counter-regulate growth and stress
responses? A functional interaction between calcineurin and
TOR has been suggested by a two-hybrid interaction between
CNA (CNA1 or CNA2) and the TORC2 phosphorylation sub-
strates SLM1 and SLM2 (12). The homologous SLM1 and
SLM2 are redundant, essential proteins that control polariza-
tion of the actin cytoskeleton by an unknown mechanism (13,
14). In this study we show that TORC2 and calcineurin inhibit
each other via the SLMproteins. Our findings provide amolec-
ular mechanism for themutual antagonism of growth-promot-
ing and growth-inhibiting signaling pathways. Furthermore, we
show that TORC2 controls transcription and has a pivotal role
in the negative regulation of calcineurin-dependent stress
signaling, in addition to controlling organization of the actin
cytoskeleton.
EXPERIMENTAL PROCEDURES
Strains, Plasmids, andMedia—The S. cerevisiae strains and
plasmids used in this study are listed in Table 1. All strains
are isogenic derivatives of TB50 or JK9-3d. Medium (YPD/
YPGal) was prepared as described previously (15, 16). YPD
containing 0.2 M CaCl2 was prepared by adding the required
volume of a 1 M stock of CaCl2 to 1.25-fold concentrated,
autoclaved YPD. FK506 was added to a final concentration of
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2 g/ml from a 1 mg/ml stock in 90% ethanol-10% Tween 20.
FK506 treatment was for 30 min. H2O2 was added from a
30% commercial solution (Fluka) to autoclaved YPD agar
medium prior to solidification to a final concentration of 5
mM. For TOR2-, AVO3-, and SLM2-depletion experiments,
YPGal cultures of logarithmically growing cells, condition-
ally expressing the corresponding genes from the GAL1 pro-
moter, were inoculated into YPD medium and incubated
with aeration for 15 (TOR2 or AVO3 depletion) or 6 h (SLM2
depletion). The long incubation times reflect the amount of
time required to deplete the proteins in question (17). PCR
cassettes were used to generate gene deletions and epitope
tags in the genome as described previously (18). An SLM
mutant lacking the PxIxIT-related, putative calcineurin
docking site was constructed by replacing the C-terminal 14
amino acids of SLM1with aMyc or TAP tag in the genome as
described above.
RNA Isolation,Microarray, and Northern Blot Analysis—For
the microarray experiment, S. cerevisiae strains SH100 and
SH121 (19) were grown at nonpermissive temperature (37 °C)
for 6 h, as described (20). Total RNA was extracted using a hot
phenol method essentially as described (21). AffymetrixTM S98
Yeast Genome GeneChips, containing 6,400 S. cerevisiae
(S288C strain) genes, were used. Two independent RNA prep-
arations were used for each strain. Quantity and quality of total
RNA were determined by capillary electrophoresis on a
RNA6000 Bioanalyzer (Agilent Technologies). Synthesis of
cDNA, in vitro transcription of biotin-labeled cRNA, microar-
ray hybridization, washing, and staining procedures were car-
ried out according to standard protocols as recommended by
the manufacturer (Affymetrix). Data normalization was per-
formed using the Robust Multi-array Analysis algorithm as
implemented in GeneSpring 7.2 software. For Northern blot
analysis, probe synthesis was performed by PCR using digoxy-
genin-modified dUTP, and subsequent Northern blot analysis
was performed according to the manufacturer’s protocol
(digoxygenin labeling and detection, Roche).
Coimmunoprecipitation, TAP Purification, and Immunoblott-
ing—Coimmunoprecipitations and the TAP pulldown assays
were performed as described (17). HA- andMyc-tagged pro-
teins were precipitated or detected with mouse anti-HA
antibody (clone 12CA5) or mouse anti-Myc antibody (clone
9E10). Phospho-SLM1-TAP was detected by immunoblot-
ting with anti-phosphothreonine (Q7, Qiagen) and anti-
phosphoserine (Q5, Qiagen) antibodies. Total SLM1-TAP
was detected with anti-TAP (protein A) antibody. Horserad-
ish peroxidase-conjugated anti-mouse antibody and ECL
reagents were used for immunoblots (Amersham Bio-
sciences). Proteins coprecipitating in TAP pulldowns were
excised from a 5–20% gradient gel and identified by mass
spectrometry as described (1).
In Vitro Calcineurin Assay—Phospho-SLM1-TAP was puri-
fied for use as a calcineurin substrate byTAPpull down from an
extract prepared from JM333 yeast cells (cnb1) as described
(17) but using TL buffer (40mMTris-HCl, pH 7.5, 100mMKCl,
1 mM MgCl2, 250 mM sorbitol, 1 mM dithiothreitol, 0.1% Non-
idet P-40) instead of phosphate-buffered saline buffer. The
slurry of IgG beads containing SLM1-TAPwas washed with CP
buffer (50mMTris-HCl, pH 7.5, 1 mMMgCl2, 1 mM dithiothre-
itol) containing protease inhibitors. The calcineurin reaction
TABLE 1
All strains are S. cerevisiae. Unless otherwise indicated, all the strains were constructed for this study
Strain Genotype Source
JK9-3da MATa leu2-3,112 ura3-52 trp1 his4 rme HMLa
JM229 TB50a CNA1-3HA-[His3MX6]
JM256 TB50a crz1::HIS3
JM259 TB50a CNA1-3HA-[His3MX6] SLM1-13myc-[kanMX6]
JM262 TB50a CRZ1-13myc-[His3MX6]
JM270 TB50a [His3MX6]-GAL1p-SLM2 slm1::kanMX6 CRZ1-13myc-[His3MX6]
JM271 TB50a [His3MX6]-GAL1p-SLM2 slm1::kanMX6 crz1::HIS3
JM304 TB50a cnb1::His3MX6
JM316 TB50 cnb1::His3MX6
JM321 TB50a [His3MX6]-GAL1p-AVO3 crz1::HIS3
JM324 TB50a [His3MX6]-GAL1p-AVO3 CRZ1-13myc-[His3MX6]
JM333 TB50a SLM1-TAP-[kanMX6] cnb1::His3MX6
JM338 TB50a [His3MX6]-GAL1p-TOR2 crz1::HIS3
JM340 TB50a [His3MX6]-GAL1p-TOR2 CRZ1-13myc-[His3MX6]
JM345 TB50a [His3MX6]-GAL1p-TOR2
JM347 TB50a [His3MX6]-GAL1p-AVO3
JM474 TB50a [His3MX6]-GAL1p-SLM2 slm1::kanMX6 cnb1::His3MX6
JM481 TB50a AVO3-3HA-[kanMX6] SLM1-13myc-[kanMX6] cnb1::His3MX6
JM491 TB50a SLM1-13myc-[kanMX6] CNA1-3HA-[His3MX6] cnb1::His3MX6
JM501 TB50a [His3MX6]-GAL1p-TOR2 cnb1::His3MX6
JM597 TB50a SLM1C14-TAP-[His3MX6]
JM611 TB50a SLM1C14-TAP-[His3MX6] slm2::kanMX6
JM624 TB50a SLM1C14-13myc-[His3MX6] CNA1-3HA-[His3MX6] cnb1::His3MX6
JM626 TB50a SLM1C14-13myc-[His3MX6] AVO3-3HA-[kanMX6]
JM712 TB50a SLM1C14-TAP-[His3MX6] cnb1::His3MX6
JM717 TB50a SLM1C14-TAP-[His3MX6] crz1::HIS3
RL42-1c TB50a AVO3-3HA-[kanMX6]
RL136-1a TB50 slm2::kanMX6
RL146-7d TB50a SLM1-13myc-[kanMX6]
RL164-2b TB50a AVO3-3HA-[kanMX6] SLM1-13myc-[kanMX6]
RL202-5a TB50a [His3MX6]-GAL1p-SLM2 slm1::kanMX6
RL209 TB50a SLM1-TAP-[kanMX6]
SH100 JK9-3da tor2::ADE2-3/YCplac111::TOR2 Ref. 19
SH121 JK9-3da tor2::ADE2-3/YCplac111::tor2-21ts Ref. 19
TB50a JK9-3da HIS4 his3 Hall lab.
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was performed in a total volume of 100l in CP buffer contain-
ing 500 units of recombinant human calcineurin (Calbiochem)
and 2600 units of calmodulin (Sigma) as described (22). Where
indicated, CaCl2 and EGTAwere added to a final concentration
of 40 and 10 mM, respectively. Phosphatase reactions were
incubated at 30 °C for 30 min. Phospho-SLM1-TAP and total
SLM1-TAP were detected as described above.
Microscopy—Florescence microscopy and indirect immuno-
fluorescence imaging on whole fixed cells were performed as
described (23). An anti-Myc (9E10)
antibody was used to visualize
CRZ1-Myc. Control experiments
with wild type cells showed that the
unspecific signal was negligible in
our strain. For actin cytoskeleton or
DNA staining, we used a modifica-
tion of the method described in (1),
eliminating the phosphate buffer to
avoid calcium phosphate precipita-
tion. Cells from the indicated YPD
cultures were fixed in formaldehyde
(3.7%) and stained with tetramethyl
rhodamine isothiocyanate-phalloi-
din (Sigma) to visualize actin or
4,6-diamidino-2-phenylindole to
stain DNA and visualize nuclei.
Actin cytoskeleton organization
was assessed in several hundred
cells as described (19).
RESULTS
TORC2 Negatively Controls Cal-
cineurin-dependent Transcription—
TORC2, because of its rapamycin
insensitivity, is less well character-
ized than TORC1. To further inves-
tigate TORC2, we performed a
genome-wide transcriptome analy-
sis on an S. cerevisiae strain (SH121)
containing the thermosensitive
tor2–21 (tor2ts) allele (19). This
strain is defective for TORC2 but
not for TORC1 (1, 17). At nonper-
missive temperature, 90 genes
were up-regulated (2-fold induc-
tion), and no genes were signifi-
cantly down-regulated in the tor2ts
mutant, compared with wild type
(Fig. 1). This suggests that TORC2
controls transcription,mainly nega-
tively. Further analysis revealed that
50% of the genes inhibited by
TORC2 overlapped with a set of
genes, the expression of which was
dependent on calcineurin andCRZ1
(24) (Fig. 1). The overlapping genes
include those most dependent on
calcineurin and CRZ1 for expres-
sion (5.5-fold induction upon calcineurin activation). These
findings suggest that TORC2 inhibits calcineurin and CRZ1.
To determine whether TORC2 indeed inhibits CRZ1,
we examined CRZ1-dependent transcription directly in a
tor2 mutant and in a mutant defective for the TORC2-
specific subunit AVO3. Transcripts corresponding to the
CRZ1 target genes CMK2, DIA1, YLR194c, and YOR385w
were probed by Northern analysis in strains conditionally
expressing TOR2 or AVO3 from the galactose-inducible and
FIGURE 1.Microarray analysis of a tor2mutant defective in TORC2.A, summary of DNAmicroarray analysis.
Genes induced in a calcineurin/CRZ1-dependent manner (24) and those induced in a tor2ts mutant are com-
pared. B, names and brief descriptions of the genes included in the diagram intersection in A. Rawmicroarray
data files can be found in the NCBI GEO repository under the series number GSE1814.
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glucose-repressible GAL1 promoter. Strains conditionally
expressing TOR2 or AVO3 were used, instead of strains
containing a thermosensitive tor2 or avo3 allele, to avoid
potential complications because of heat stress activation
of CRZ1. The CRZ1 target genes were induced upon
depletion of TOR2 or AVO3 and in the absence of any
other stress (Fig. 2A; data not shown for YOR385w).
The CRZ1 dependence of the examined transcripts was
determined by deleting CRZ1 in the tor2 and avo3 strains
(Fig. 2A). We also observed cal-
cineurin-dependent response ele-
ment (CDRE)-dependent expression
of lacZ upon TOR2 or AVO3
depletion (data not shown). These
experiments confirm the results of
the transcriptome analysis with the
tor2ts mutant and indicate that the
expression changes observedwith the
tor2ts mutant are not necessar-
ily because of heat stress. Thus,
TORC2 inhibits CRZ1-dependent
transcription under normal growth
conditions, i.e. in the absence of
stress.
Calcineurin dephosphorylates
CRZ1 and thereby triggers nuclear
localization and activation of CRZ1
(25). To investigate whether
TORC2 regulates calcineurin, we
examined CRZ1 localization in the
tor2 and avo3 mutants by indirect
immunofluorescence on whole
fixed cells (Fig. 2B). In both tor2 and
avo3mutant cells, CRZ1 was exclu-
sively (15–20% of cells) or mainly
(45–50% of cells) nuclear, whereas
in wild type cells CRZ1 was exclu-
sively or mainly cytoplasmic. Thus,
TORC2 inhibits nuclear accumula-
tion of CRZ1. To investigate the
calcineurin-dependence of CRZ1
nuclear localization in the tor2 and
avo3 mutants, cells were treated
with the calcineurin inhibitor
FK506. A short treatment (30 min)
with FK506 restored cytoplasmic
localization of CRZ1 in tor2 and
avo3 cells (Fig. 2B). Similar suppres-
sion of the CRZ1 localization defect
was obtained upon deletion of
CNB1 encoding the positive regula-
tory subunit of calcineurin (data not
shown). Thus, CRZ1 nuclear local-
ization in the tor2 and avo3mutants
was calcineurin-dependent. The
above findings suggest that TORC2
negatively regulates calcineurin.
However, these experiments do not
distinguish whether the TORC2 inhibits calcineurin directly or
indirectly.
TORC2 Inhibits Calcineurin via the SLM Proteins—The
observation that the TORC2 substrates SLM1 and SLM2 inter-
act with the catalytic subunit of calcineurin (CNA1 or CNA2),
as revealed by a genome-wide two-hybrid study (12), suggests
that TORC2 inhibits calcineurin via the SLMs. To investigate
this possibility, we examined CRZ1-dependent transcription
and CRZ1 localization in a slm1 slm2 double mutant (slm1,2).
FIGURE 2. TORC2 negatively regulates calcineurin and CRZ1 via the SLM proteins. A, CRZ1-dependent
transcription is constitutively activated in TORC2mutants. Transcripts of the indicated CRZ1 target geneswere
visualized in the indicated strains, wt (TB50a), tor2 (JM345), avo3 (JM347), crz1 (JM256), tor2 crz1 (JM338), avo3
crz1 (JM321), by Northern analysis. B, the calcineurin-dependent transcription factor CRZ1 localizes to the
nucleus in tor2 and avo3 mutant. This constitutive localization is abolished upon inhibition of calcineurin by
addition of FK506 to cells. CRZ1 localization (CRZ1) was examined in the following strains: wt (JM262), tor2
(JM340), and avo3 (JM324). In all cases, a monoclonal anti-Myc antibody was used as a primary antibody for
indirect immunofluorescence.DNAwasstainedwith4,6-diamidino-2-phenylindoletovisualizenuclei.C,CRZ1-
dependent transcription is constitutively activated in slm1,2mutants. Transcripts of the indicated CRZ1 target
genes were visualized in the indicated strains, wt (TB50a), slm1,2 (RL202-5a), crz1 (JM256), slm1,2 crz1 (JM271),
byNorthernanalysis.D, the calcineurin-dependent transcription factorCRZ1 localizes to thenucleus in a slm1,2
mutant. This constitutive localization is abolished upon inhibition of calcineurin by addition of FK506 to cells.
CRZ1 localization (CRZ1) was examined in a wt (JM262) and in a slm1,2 mutant (JM270). In all cases, a mono-
clonal anti-Myc antibody was used as a primary antibody for indirect immunofluorescence. DNA was stained
with 4,6-diamidino-2-phenylindole to visualize nuclei. E, deletion of the regulatory subunit of calcineurin
(CNB1) suppresses the lethality of a conditional slm1,2mutant. Strain slm1,2 cnb1 (JM474) was constructed by
crossing strain slm1,2 (RL202-5a)with cnb1 (JM316) and selecting strainswith the appropriatemarkers. Growth
of the indicated strains was tested on permissive (YPGal) and nonpermissive (YPD) medium by incubating the
different plates for 3 days at 30 °C. F, CNB1mutation suppresses the actin depolarization phenotype of a slm1
slm2doublemutant (slm1,2). Strains described in Ewere grown in restrictive (YPD)medium tomid-logarithmic
phase, fixed, and stained for F-actin using rhodamine-phalloidin (ACTIN). Cells were visualized using Nomarski
optics (NOM).
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Because the SLMs are essential, strains containing a SLM1 dele-
tion and conditionally expressing SLM2 from the GAL1
promoter were used for these experiments. In a slm1,2mutant,
CRZ1 accumulated in the nucleus in a calcineurin-dependent
(FK506 sensitive) manner and activated transcription of target
genes (data not shown for YOR385w) even in the absence of
stress (Fig. 2, C andD). In addition, inhibition of calcineurin by
treatment with FK506 or by deletion of CNB1 suppressed the
growth and actin defects of a slm1,2 mutant (Fig. 2, E and F).
Thus, calcineurin appears to be constitutively active in a slm1,2
mutant, like in TORC2 mutants (tor2 and avo3) and the cause
of lethality of a slm1,2 mutation. These observations suggest
that TORC2negatively regulates calcineurin via the SLMs. Fur-
thermore, the suppression of the slm1,2 actin defect by CNB1
deletion or by FK506 treatment suggests that the SLMsmediate
actin polarization via inhibition of calcineurin.
Interestingly, inhibition of calcineurin did not suppress the
lethality of a tor2 or avo3mutation (data not shown). Further-
more, multicopy ROM2 or RHO2, strong suppressors of tor2 or
avo3 lethality (1, 4), failed to suppress either the growth defect
or the CRZ1 nuclear localization phenotype of the slm1,2
mutant (data not shown) (14). Overexpression of ROM2 or
RHO2 also failed to suppress the
CRZ1 nuclear localization pheno-
type of the tor2 mutant (data not
shown). These observations suggest
that TORC2 signals via SLM-cal-
cineurin and ROM2-RHO-PKC-
MPK1/SLT2 separately.
Calcineurin Antagonizes TORC2-
SLM Signaling—TORC2 positively
controls polarization of the actin
cytoskeleton. In contrast, activation
of calcineurin causes depolarization
of the actin cytoskeleton (Fig. 2F
and Fig. 3). Furthermore, cal-
cineurin causes depolarization of
the actin cytoskeleton independ-
ently of CRZ1 (Fig. 3). These obser-
vations suggest that calcineurinmay
antagonize the ability of TORC2 to
signal via the SLMs. To address this
suggestion, we first investigated
whether calcineurin (CNA1) inter-
acts with SLM1 as suggested previ-
ously by a genome-wide two-hybrid
analysis (12). Our efforts to de-
tect, by coimmunoprecipitation, an
SLM1-CNA1 interaction in a wild
type strain were unsuccessful. As
this could be because of CNA1
dephosphorylating and thereby
releasing SLM1, we then investi-
gated an SLM1-CNA1 interaction
under conditions in which cal-
cineurin was inactive. Inhibition of
calcineurin by a cnb1mutation or by
treatment of cells with FK506
indeed resulted in detection of an
SLM1-CNA1 interaction (Fig. 4A) (data not shown for FK506).
To study further the SLM1-CNA1 interaction, we examined
whether SLM1 contained a PxIxIT calcineurin docking site.
Although we did not detect a consensus PxIxIT sequence, a
related sequence (PNIYIQ) was detected in the C-terminal 14
amino acids of SLM1 (PNIYIQ TPINDFKS). To determine
whether this PxIxIT-related sequence is a calcineurin docking
site, the C-terminal 14 amino acids of SLM1 were deleted, and
the truncated protein (SLM1C14) was assayed by coimmuno-
precipitation for interaction with CNA1. SLM1C14 failed to
interact with CNA1 even upon inhibition of calcineurin (Fig.
4A), suggesting that the PxIxIT-related sequence in SLM1was a
calcineurin binding site. The SLM1C14 mutant protein was
functional other than in its ability to interact with CNA1
because a SLM1C14 slm2 double mutant grew like a wild type
strain under standard growth conditions, unlike the slm1 slm2
doublemutant (slm1,2), whichwas nonviable (data not shown).
The above findings indicate that calcineurin interacts directly
with SLM1. Interestingly, the observation that SLM1C14 is
functional despite its inability to interact with calcineurin sug-
gests that SLM1 has a function independent of its direct inter-
action with calcineurin.
FIGURE 3. Calcineurin mediates depolarization of the actin cytoskeleton independently of CRZ1. A, wt
(TB50a), cnb1 (JM304), and crz1 (JM256) cellsweregrown inYPDmediumuntilmid-logarithmicphase and then
transferred to freshmediumcontaining0.2MCaCl2 to activate calcineurin. At the indicated times, aliquotswere
removed, fixed, and stained for F-actin using rhodamine-phalloidin (ACTIN). Cellswere visualizedusingNomar-
ski optics (NOM). B, quantitation of the actin depolarization induced by calcium. Small tomediumbudded cells
(200) of wild type (squares), cnb1 (circles), and crz1 (triangles) strains were scored for their actin polarization
state. Similar results were obtained in three separate experiments.
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We detected a physical interaction between SLM1 and the
calcineurin catalytic subunit CNA1 but only in the absence of
calcineurin activity (see above). The observation that only inac-
tive CNA1 forms a stable complex with SLM1 suggests that
calcineurin may dephosphorylate SLM1. To investigate
whether calcineurin dephosphorylates SLM1, we examined the
phosphorylation status of SLM1andSLM1C14 inwild type and
cnb1mutant cells, treated and untreated with calcium. Affinity
(TAP)-tagged SLM1 and SLM1C14 were purified and then
probed with anti-phosphoSer/Thr antibody. SLM1 was hyper-
phosphorylated in the cnb1 mutant compared with in a wild
type strain (Fig. 4B). SLM1C14, consistent with its inability to
interact with calcineurin, was hyperphosphorylated under all
conditions examined (Fig. 4B). These findings suggest that cal-
cineurin dephosphorylates SLM1 in vivo. Furthermore, recom-
binant calcineurin (plus calmodulin) dephosphorylated puri-
fied phospho-SLM1-TAP in vitro (Fig. 4C). This observation,
combined with the previous observation that SLM1 physically
interacts with calcineurin, suggests that calcineurin dephos-
phorylates SLM1 directly.
To investigate the functional consequence of SLM1 hyper-
phosphoryation, we examined the interaction between SLM1
and TORC2 in wild type and cnb1 mutant cells. The TORC2-
SLM interaction is weak (13, 14) and undetectable in our exper-
imental conditions, as assayed by coimmunoprecipitation of
SLM1 with AVO3 or TOR2 (Fig. 5, A and B). Inhibition of
calcineurin, upon introduction of a cnb1mutation or treatment
of cells with FK506, significantly enhanced the binding of SLM1
to both AVO3 and TOR2 (Fig. 5, A and B) (data not shown for
FK506). Furthermore, the SLM1C14 variant that was unable to
bind calcineurin also exhibited enhanced binding to AVO3 and
TOR2 (Fig. 5, A and B). Thus, calcineurin both dephospho-
rylates SLM1 and inhibits the TORC2-SLM1 interaction, sug-
gesting that calcineurin antagonizes TORC2-SLM signaling.
To investigate further the physiological significance of SLM1
phosphorylation, we performed a more extensive phenotypic
analysis of the SLM1C14 slm2 mutant, which grew like wild
type under normal growth conditions. The SLM1C14 slm2
mutantwas exposed to various stress conditions, including heat
(37 °C), cold (15 °C), osmotic (1.8 M sorbitol or 1 M NaCl), lith-
ium (0.3 M), calcium (0.2 M CaCl2), and oxidative (5 mM H2O2)
stress. The SLM1C14 slm2 was hypersensitive specifically to
oxidative stress, as evidenced by a growth defect only in the
presence ofH2O2 (Fig. 5C and data not shown). Thus, phospho-
rylated SLM1 prevents the cellular response to oxidative stress,
suggesting that TORC2-SLM signaling inhibits the response to
this stress. In other words, calcineurin inhibits the ability of
TORC2-SLM signaling to keep the response to oxidative stress
at bay. A crz1mutation failed to confer hypersensitivity to oxi-
dative stress, indicating that TORC2-SLM2 signaling inhibited
the response to oxidative stress independently of CRZ1-
dependent transcription.
DISCUSSION
We have presented evidence that TORC2-SLM signaling
inhibits calcineurin, and conversely, calcineurin inhibits
TORC2-SLM signaling. According to this model (Fig. 6),
TORC2 phosphorylated the SLM proteins (13, 14) and thereby
inhibited calcineurin and calcineurin-mediated events such as
actin cytoskeleton depolarization and CRZ1-dependent tran-
scription. Conversely, calcineurin dephosphorylates the SLMs
and thereby inhibits TORC2-SLM signaling to the oxidative
stress response and possibly other effectors. Thus, TORC2 and
calcineurin are mutually antagonistic. The logic of this mutual
antagonismmay be the need to cope with the conflicting states
of growth and stress. TORC2 prevents the calcineurin-acti-
vated stress response during favorable conditions, and con-
versely, calcineurin prevents TOR-mediated growth during
FIGURE 4. SLM1 is a target of calcineurin. A, CNA1 and SLM1 interact in a
calcineurin-sensitive manner. Cells expressing epitope-tagged CNA1 (CNA1-
HA) (JM229), SLM1 (SLM1-Myc) (RL146-7d), co-expressing both tagged pro-
teins (JM259 and JM491) or co-expressing epitope-tagged CNA1 with an
epitope-tagged version of SLM1 (SLM1C14) lacking the C-terminal 14 amino
acids (SLM1C14-Myc) (JM624), were grown to mid-logarithmic phase, har-
vested, lysed, and cell extracts were subjected to immunoprecipitation with
anti-HA (IP: CNA1). Immunoprecipitates were probedwith anti-Myc to detect
coimmunoprecipitated SLM1 protein (coIP: SLM1). CNA1 and SLM1 interact
only in a cnb1 mutant. B, calcineurin dephosphorylates SLM1 in vivo. SLM1-
TAP (RL209), SLM1-TAP cnb1 (JM333), SLM1C14-TAP (JM597), and SLM1C14-
TAP cnb1 (JM712) cells were grown to mid-logarithmic phase and either
mock-treated or treated with 200 mM CaCl2 for 10 min. Cells were harvested
and subjected to protein extraction and TAP purification, SDS-PAGE, and
immunoblotting. The immunoblottingwas performedwith an anti-TAP (pro-
tein A) antibody to detect total SLM1-TAP (SLM1) or SLM1C14-TAP
(SLM1C14) or with a mixture of commercial antibodies against phosphoryla-
ted serine and phosphorylated threonine to detect phospho-SLM1-TAP
(SLM1-pS/T) or phospho-SLM1C14-TAP (SLM1C14-pS/T) (see “Experimental
Procedures”). C, calcineurin dephosphorylates phospho-SLM1 in vitro. Phos-
pho-SLM1-TAP (SLM1-pS/T) was purified from cnb1 cells (JM333) and treated
with recombinant calcineurin (plus calmodulin), CaCl2, and EGTAas indicated
and described under “Experimental Procedures.” SLM1-pS/T and total SLM1-
TAP (SLM1) were detected as described above.
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stress. The inhibition of calcineurin byTORC2 also allows a cell
to resume growth after a stress has been overcome. Finally,
another noteworthy aspect of the model (Fig. 6), which is sug-
gested by our finding that a cnb1 mutation suppresses the
slm1,2 actin defect, is that the SLMsmediate actin cytoskeleton
polarization via inhibition of calcineurin. The observation that
the SLM1C14mutation has no effect on the actin cytoskeleton
(data not shown) is further evidence for this notion. Although
not shown in ourmodel, the pleckstrin homology domain-con-
taining SLM proteins also respond to the phosphatidylinositol-
4-phosphate 5-kinase MSS4 (13, 14).
Is the mutual antagonism of calcineurin and TORC2-SLM
direct or indirect? The observations that calcineurin binds the
SLMs, and that calcineurin dephosphorylates SLM1 in vivo and
in vitro suggest that calcineurin inhibits TORC2-SLM signaling
by acting on SLM directly. The mechanism of inhibition in the
other direction by which TORC2-SLM inhibits calcineurin is
less clear. It seems unlikely that TORC2-SLM inhibits cal-
cineurin directly because SLM1 in the SLM1C14 slm2mutant
is unable to bind calcineurin, and yet this mutant grows nor-
mally and is thus still able to inhibit calcineurin. Furthermore,
the observation that the SLM1C14 slm2mutant responds nor-
mally to salt stress (i.e. calcineurin activation) suggests that
SLM dephosphorylation by calcineurin is not required to acti-
vate calcineurin. How might TORC2-SLM inhibit calcineurin
indirectly? We were unable to detect a change in the concen-
tration of cytoplasmic calcium in tor2 and avo3 mutants, as
assayed with a calcium-specific dye (Fluo-3 AM) (data not
shown), suggesting that TORC2-SLM inhibits calcineurin by a
mechanism other than the modulation of cytoplasmic calcium.
Another possibility is that TORC2-SLMmodulates the activity
of the calcineurin regulator RCN1 (26). Indeed, RCN1 tran-
scription is up-regulated in the tor2tsmutant at nonpermissive
FIGURE 5.Calcineurin inhibits the interaction between TORC2 and SLM1.
A, interaction of TORC2 component AVO3 with SLM1 is calcineurin-sensitive.
Cells expressing epitope-tagged AVO3 (AVO3-HA) (RL42-1c), SLM1 (SLM1-
Myc) (RL146-7d), both (RL164-2band JM491), orAVO3andanepitope-tagged
version of SLM1C14 (SLM1C14-Myc) (JM626) were grown to mid-logarithmic
phase, harvested, and lysed, and cell extracts were subjected to immunopre-
cipitation with anti-HA (IP: AVO3). Immunoprecipitates were probed with
anti-Myc to detect coimmunoprecipitated SLM1 protein (coIP: SLM1). AVO3
and SLM1 interacted in a cnb1mutant, or when the 14 C-terminal residues of
SLM1 were deleted. B, interaction of TOR2 with SLM1 is calcineurin-sensitive.
Lysates from wild type (mock purification), SLM1-TAP (RL209), SLM1-TAP
cnb1 (JM333), and SLM1C14-TAP (JM597) strains were subjected to TAP puri-
fication (IP: SLM1). Proteins were separated in a 5–20% gradient gel and
stainedwith coomassie. TOR2 (coIP: TOR2) and SLM1were identified bymass
spectrometry. TOR2 and SLM1 interacted in a cnb1 mutant, or when the C
terminus of SLM1 was truncated. C, SLM1C14 slm2 is sensitive to hydrogen
peroxide. The indicated strains wt (RL209), cnb1 (JM333), crz1 (JM717), and
SLM1C14 slm2 (JM611) were grown to saturation in rich medium, serially
diluted in water (1/10, 1/100, and 1/1000), and spotted on YPD agar or YPD
agar containing the indicated compound. Growth was recorded after 48 to
72 h of incubation at 30 °C.
FIGURE 6. Model for mutual antagonism TORC2 and calcineurin signal-
ing. Stress induces a rise in cytoplasmic calcium that activates calcineurin.
Activated calcineurindephosphosphorylates theSLMproteins andCRZ1. Cal-
cineurin-meditated dephosphorylation of SLM disrupts signaling to the oxi-
dative stress response and possibly other targets. In the absence of stress,
TORC2 signals through the SLMs to control calcineurin and the oxidative
stress response. SLM1,2 is required to block calcineurin signaling in normal
growth conditions.
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temperature (Fig. 1). The mechanism by which TORC2-SLM
inhibits calcineurin remains to be determined.
We present evidence that TORC2 inhibits calcineurin/
CRZ1-dependent transcription and the oxidative stress
response. Furthermore, TORC2 seems to control these two
new readouts independently of the previously characterized
RHO-PKC1-MPK1 effector pathway (Fig. 6). AlthoughTORC1
has been known for some time to control several cellular pro-
cesses via different effector pathways, TORC2 was thought to
signal only to the actin cytoskeleton and only via the RHO-
PKC-MPK1 pathway. TORC2, like TORC1, now appears to
have multiple effectors and targets. The complexity of TORC2
signaling has been underestimated possibly because TORC2 is
rapamycin-insensitive, and studies on TOR function have usually
relied on rapamycin to inhibit TOR signaling. Interestingly, an
important aspect of TORC1 signaling in both yeast andmamma-
lian cells is the inhibition of type 2A and type 2A-related phospha-
tases (27). Our observations suggest that TORC2 also signals via
inhibition of a phosphatase, in this case calcineurin.
How does TORC2-SLM signaling inhibit the oxidative stress
response? Yokoyama et al. (28) have suggested that YAP1, a
transcription factor mediating the oxidative stress response, is
controlled by calcineurin. Thus, an appealing model is that
TORC2-SLM signaling inhibits the oxidative stress response by
inhibiting YAP1. In the absence of stress, SLM is phosphoryla-
ted and bound to TORC2 and could thereby serve as an adaptor
presenting YAP1 to TORC2 for phosphorylation and inhibi-
tion. Alternatively, as YAP1 is regulated at the level of nuclear
localization, phosphorylated SLM could simply bind and
sequester YAP1. In response to stress, calcineurin dephospho-
rylates SLM and possibly YAP1, leading to activation of YAP1.
Interestingly, at least three CRZ1-independent YAP1 target
genes (CTT1, ARG4, and LAP4) are up-regulated in the tor2ts
mutant at nonpermissive temperature (www.ncbi.nlm.nih.gov/
geo/; accession number GSE1814). It is also interesting to note
that TOR controls nuclear localization of several stress-related
transcription factors, including GLN3, GAT1,MSN2/4, RTG1,
RTG3, and as shown here, CRZ1 (15, 29, 30).
Does mTOR inhibit calcineurin in mammalian cells? mTOR
promotes skeletal myotube hypertrophy in response to insulin-
like growth factor-1, and this effect is enhanced by the cal-
cineurin inhibitor cyclosporin A (31). Furthermore, mTORC2
mediates actin polymerization inmammalian cells (32, 33), and
calcineurin induces F-actin destabilization in dendritic spines
(34). Thus, mTORC2 may inhibit calcineurin also in mamma-
lian cells. mTORC2 signaling, which like TORC2 signaling in
yeast is rapamycin-insensitive, probably has a broader role in
the control of cell growth than commonly appreciated.
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